TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11579248

Group type: EXPERIMENTAL
Intervention: bDNA assay for HIV-1 RNA
Number of subjects: 106
Study: 10378439

Group type: EXPERIMENTAL
Intervention: Adaptive automation system using EEG engagement indices (beta/(alpha + theta), beta/alpha, or 1/alpha)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive automation system using absolute levels of engagement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative feedback condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta/(alpha + theta) index
Number of subjects: 0
Study: 7493311

Group type: EXPERIMENTAL
Intervention: rIFN-alpha 3 MU thrice weekly (group A)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: rIFN-alpha 6 MU thrice weekly (group B)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: L-IFN 3 MU thrice weekly (group C)
Number of subjects: 112

Group type: COMPARATOR
Intervention: No treatment (group D)
Number of subjects: 112
Study: 2148877

Group type: EXPERIMENTAL
Intervention: Peri-operative chemotherapy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (no peri-operative chemotherapy)
Number of subjects: 53
Study: 6995640

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 232

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 232
Study: 31852118

Group type: EXPERIMENTAL
Intervention: Cortex Eucommiae (CE) extract for 12 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 100
Study: 28961845

Group type: EXPERIMENTAL
Intervention: 600 mg apatorsen
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: 1000 mg apatorsen
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: 600 mg apatorsen (poor prognostic features)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: 600 mg apatorsen (lower sHsp27 levels)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: 1000 mg apatorsen (lower sHsp27 levels)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 25742559

Group type: EXPERIMENTAL
Intervention: Acoustic wave therapy (AWT)
Number of subjects: 15
Study: 24444704

Group type: EXPERIMENTAL
Intervention: Perineal retraining (biofeedback)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Standard conservative treatment (control)
Number of subjects: 157
Study: 22458860

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Amodiaquine (AQ)
Number of subjects: 300
Study: 19829175

Group type: EXPERIMENTAL
Intervention: Lifestyle changes, pharmacotherapy, and psychologic interventions
Number of subjects: 0
Study: 17459081

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 81
Study: 15333884

Group type: EXPERIMENTAL
Intervention: 30 second anti‐smoking advertisement shown before the movie in week 2
Number of subjects: 2038

Group type: COMPARATOR
Intervention: Control group surveyed during week 1
Number of subjects: 2038
Study: 11231437

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 320

Group type: COMPARATOR
Intervention: eptifibatide
Number of subjects: 320
Study: 11323363

Group type: EXPERIMENTAL
Intervention: Small Ketamine (0.25 mg/kg)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Large Ketamine (1.0 mg/kg)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 85
Study: 9217714

Group type: EXPERIMENTAL
Intervention: Picotamide, 600 mg twice daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 22
Study: 8394749

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Presence of rhinovirus
Number of subjects: 71

Group type: COMPARATOR
Intervention: Other viruses (respiratory syncytial virus, parainfluenza virus, influenza virus)
Number of subjects: 71
Study: 3118579

Group type: EXPERIMENTAL
Intervention: Insulin plus glibenclamide
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Glibenclamide withdrawal
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 79

Group type: COMPARATOR
Intervention: Short-term effects
Number of subjects: 79
Study: 2256787

Group type: EXPERIMENTAL
Intervention: Cefotaxime continued treatment
Number of subjects: 101

Group type: COMPARATOR
Intervention: Ampicillin replacement treatment
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Phenobarbitone administration
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: IV treatment cessation by the 10th day
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Initial treatment with IIIrd generation cephalosporin
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Substitution by ampicillin or amoxicillin
Number of subjects: 101
Study: 1137256

Group type: EXPERIMENTAL
Intervention: Computer-assisted digoxin therapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Physician-regulated digoxin therapy
Number of subjects: 51
Study: 30741577

Group type: EXPERIMENTAL
Intervention: Self-ligating (SL) brackets
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional (CV) brackets
Number of subjects: 25
Study: 28244929

Group type: EXPERIMENTAL
Intervention: Shoelace ACL Simulation Guide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Instructional video only
Number of subjects: 10
Study: 25395071

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 24925984

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400 mg
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Oral aripiprazole (10-30 mg/day)
Number of subjects: 662

Group type: COMPARATOR
Intervention: Aripiprazole once-monthly 50 mg
Number of subjects: 662
Study: 22552758

Group type: EXPERIMENTAL
Intervention: Saffron (15 mg twice per day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 19912088

Group type: EXPERIMENTAL
Intervention: Fagerström Test for Nicotine Dependence (FTND)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Self-reported smoking status
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Urinary cotinine concentrations
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Number of cigarettes smoked
Number of subjects: 201
Study: 17878429

Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation (group N)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Manual operation (group M)
Number of subjects: 53
Study: 15523183

Group type: EXPERIMENTAL
Intervention: Insulin lispro (LP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Regular human insulin (RH)
Number of subjects: 27
Study: 12490271

Group type: EXPERIMENTAL
Intervention: Angiopeptin 1.5 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intracoronary ultrasound (sub-group of patients)
Number of subjects: 31
Study: 9620513

Group type: EXPERIMENTAL
Intervention: Ketamine 0.4 mg/mL
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control (without ketamine)
Number of subjects: 91
Study: 7542134

Group type: EXPERIMENTAL
Intervention: Finasteride (Proscar) therapy for BPH
Number of subjects: 30
Study: 2377755

Group type: EXPERIMENTAL
Intervention: Radionuclide scintigraphy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Barium meal X-ray
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combined use of barium X-ray and scintigraphy
Number of subjects: 31
Study: 205811

Group type: EXPERIMENTAL
Intervention: 1300 international units of vitamin D2/d
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 4000 international units of vitamin D2/d
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 1300 international units of vitamin D3/d
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 4000 international units of vitamin D3/d
Number of subjects: 86
Study: 31660918

Group type: EXPERIMENTAL
Intervention: Comprehensive Sexuality Education (CSE) intervention
Number of subjects: 1096

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1096
Study: 28522433

Group type: EXPERIMENTAL
Intervention: Educative website on suicide prevention
Number of subjects: 161

Group type: COMPARATOR
Intervention: Unrelated website (control group)
Number of subjects: 161
Study: 25528143

Group type: EXPERIMENTAL
Intervention: Combined users (alcohol and energy drinks in the same beverage or on the same occasion)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Separate users (alcohol and energy drinks on separate occasions)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Non-Users (those who drank alcohol, but not energy drinks)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Combined users
Number of subjects: 439
Study: 23085971

Group type: EXPERIMENTAL
Intervention: 20,000 kg load-volume
Number of subjects: 8

Group type: COMPARATOR
Intervention: 10,000 kg load-volume
Number of subjects: 8
Study: 21303566

Group type: EXPERIMENTAL
Intervention: Deep TMS applied for 10 min (600 pulses per session) to the left temporoparietal cortex for either 10 or 20 sessions.
Number of subjects: 8
Study: 19736899

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (5 microg) plus intrathecal morphine (150 microg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Intrathecal sufentanil (5 microg) plus single administration of 10 mg subcutaneous morphine
Number of subjects: 64
Study: 17163810

Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitaxsentan with concomitant warfarin
Number of subjects: 0
Study: 15068753

Group type: EXPERIMENTAL
Intervention: Tailored nutrition education CD-ROM program
Number of subjects: 307

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 307
Study: 11402112

Group type: EXPERIMENTAL
Intervention: Cerebral white matter lesions (WML) severity
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: Severe WML
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: Periventricular WML
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: Subcortical WML
Number of subjects: 1049
Study: 9640068

Group type: EXPERIMENTAL
Intervention: Sympathetic skin response examination in patients with MS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Heart rate variability tests in patients with MS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Blood pressure response to standing in patients with MS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clinical examination in patients with MS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sympathetic skin response examination in controls
Number of subjects: 24
Study: 7958673

Group type: EXPERIMENTAL
Intervention: High transcutaneous electrical nerve stimulation (100 Hz, 100 microseconds)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No somatic stimulation (control)
Number of subjects: 8
Study: 2521722

Group type: EXPERIMENTAL
Intervention: Opium (10(30) dilution, 15 HC)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Raphanus (10(10) dilution, 5 HC)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Opium and placebo of Raphanus
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebos of both products
Number of subjects: 600
Study: 52854

Group type: EXPERIMENTAL
Intervention: Oxprenolol (60 mg per day) and Quinidine (0.60 g per day)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Quinidine (0.80 g per day)
Number of subjects: 184
Study: 30676622

Group type: EXPERIMENTAL
Intervention: Avelumab, 10 mg/kg, every 2 weeks until disease progression, unacceptable toxic effects, or withdrawal from the study
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 125
Study: 29975403

Group type: EXPERIMENTAL
Intervention: Home-based walking exercise
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 213
Study: 26729394

Group type: EXPERIMENTAL
Intervention: Usual care and early electrical stimulation (ES) to the wrist flexors and extensors for 30 min twice a day, 5 days a week for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 24375295

Group type: EXPERIMENTAL
Intervention: 14-Fr pigtail catheter
Number of subjects: 40

Group type: COMPARATOR
Intervention: 28-Fr chest tube
Number of subjects: 40
Study: 22151064

Group type: EXPERIMENTAL
Intervention: 10 mg · kg(‐1) GHB
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 25 mg · kg(‐1) GHB
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 50 mg · kg(‐1) GHB
Number of subjects: 36
Study: 20619853

Group type: EXPERIMENTAL
Intervention: Zinc sulfate (10 or 20 mg/day depending on age) for 10 days
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 141
Study: 17195697

Group type: EXPERIMENTAL
Intervention: Hib-MenC coadministered with DTPa-HBV-IPV
Number of subjects: 237

Group type: COMPARATOR
Intervention: MenC-CRM coadministered with DTPa-HBV-IPV/Hib
Number of subjects: 237
Study: 15726891

Group type: EXPERIMENTAL
Intervention: High-AGE (AGE 2.4 ml/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Low-AGE (AGE 0.16 ml/day)
Number of subjects: 51
Study: 12240812

Group type: EXPERIMENTAL
Intervention: Tailored hospital intervention (workshops, policy review, multidisciplinary meetings, rounds, unit discussions)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tailored hospital intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no tailored intervention)
Number of subjects: 200
Study: 9853997

Group type: EXPERIMENTAL
Intervention: Cryo/Cuff (group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wound dressing (group 2)
Number of subjects: 30
Study: 8136443

Group type: EXPERIMENTAL
Intervention: Group education (intervention group)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Individual education (control group)
Number of subjects: 160
Study: 2813561

Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 8
Study: 1175910

Group type: EXPERIMENTAL
Intervention: Electric acupuncture
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo suppository
Number of subjects: 15
Study: 31174215

Group type: EXPERIMENTAL
Intervention: MMN (without iron)
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: Fe + MMN
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: Fe (60 mg)
Number of subjects: 760

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 760
Study: 27798075

Group type: EXPERIMENTAL
Intervention: 150 mg of mephedrone administered orally
Number of subjects: 6
Study: 26354530

Group type: EXPERIMENTAL
Intervention: Lowest Dietary Inflammatory Index (DII) score (anti-inflammatory diet)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Decrease in DII (greater anti-inflammatory potential of the diet)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Highest DII tertile (pro-inflammatory diet)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Greatest pro-inflammatory values after 5-year follow-up
Number of subjects: 520
Study: 24228535

Group type: EXPERIMENTAL
Intervention: Immune 2 plus HAART
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo plus HAART
Number of subjects: 264
Study: 21843835

Group type: EXPERIMENTAL
Intervention: Customised foot orthoses
Number of subjects: 400

Group type: COMPARATOR
Intervention: No shoe insert or orthosis (Control)
Number of subjects: 400
Study: 17574300

Group type: EXPERIMENTAL
Intervention: Questionnaire on Craving for Sweet or Rich Foods (QCSRF)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Factor 1 (six items assessing perceptions about sweet or rich foods)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Factor 2 (three items assessing intensity of cravings)
Number of subjects: 385
Study: 16922941

Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser (PDL) therapy following 30% Salicylic Acid (SA) application twice a day for 5 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Pulsed Dye Laser (PDL) therapy alone
Number of subjects: 19
Study: 12712081

Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment for three cycles followed by placebo for one cycle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment for three cycles followed by placebo for one cycle
Number of subjects: 0
Study: 11085959

Group type: EXPERIMENTAL
Intervention: Circulating immune complexes (CICs)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: IgG antibodies to cardiolipin
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: C4 null alleles
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: CICs and autoantibodies against cardiolipin
Number of subjects: 257
Study: 8638014

Group type: EXPERIMENTAL
Intervention: Spiral CT with pitch 1.2
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Spiral CT with pitch 1.5
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Spiral CT with pitch 2.0
Number of subjects: 109

Group type: COMPARATOR
Intervention: Spiral CT with standard pitch (1.0)
Number of subjects: 109
Study: 8500859

Group type: EXPERIMENTAL
Intervention: Captopril monotherapy or combined with hydrochlorothiazide
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional therapy (metoprolol, hydrochlorothiazide, or both)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Captopril or conventional therapy
Number of subjects: 74
Study: 29396092

Group type: EXPERIMENTAL
Intervention: Romiplostim (750 μg subcutaneously once per week for 58 weeks)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 24296848

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 5518

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5518

Group type: EXPERIMENTAL
Intervention: Fenofibrate and TZD
Number of subjects: 5518

Group type: COMPARATOR
Intervention: Neither fenofibrate nor TZD
Number of subjects: 5518
Study: 22482610

Group type: EXPERIMENTAL
Intervention: Curvilinear approach for prostate seed implantation
Number of subjects: 20
Study: 19672050

Group type: EXPERIMENTAL
Intervention: Shuttle Walking Test (SWT)
Number of subjects: 50
Study: 18593491

Group type: EXPERIMENTAL
Intervention: Pressure-Support Ventilation (PSV)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Volume Controlled-Continuous Mandatory Ventilation (VC-CMV)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Pressure-Regulated Volume-Control Ventilation (PRVC)
Number of subjects: 14
Study: 15809384

Group type: EXPERIMENTAL
Intervention: Intervention group taught a system using heart sounds as an internal reference
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 100
Study: 11920549

Group type: EXPERIMENTAL
Intervention: Individualized uncertainty management intervention delivered by telephone (weekly phone calls for 8 weeks)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 239
Study: 10507379

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study: 7557711

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 2
Study: 2113376

Group type: EXPERIMENTAL
Intervention: Short course (SC) of systemic antibiotics
Number of subjects: 203

Group type: COMPARATOR
Intervention: Long course (LC) of systemic antibiotics
Number of subjects: 203
Study: 391657

Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg on entering the study followed by 400 mg six hourly)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 31348053

Group type: EXPERIMENTAL
Intervention: Prehabilitation group (n = 37)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (n = 36)
Number of subjects: 73
Study: 31614295

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training for 8 weeks, 7 days per week, twice daily
Number of subjects: 47
Study: 27149590

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo Kinesio Tape (KT)
Number of subjects: 42
Study: 26052875

Group type: EXPERIMENTAL
Intervention: CBT + I/EP
Number of subjects: 83

Group type: COMPARATOR
Intervention: CBT + SL
Number of subjects: 83
Study: 23535796

Group type: EXPERIMENTAL
Intervention: Aerobic cycling training (12 weeks, 5 times/week)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 128
Study: 21487251

Group type: EXPERIMENTAL
Intervention: Abacavir, lamivudine and nevirapine or efavirenz; children in induction-maintenance arms also received zidovudine to week 36; Pre-ART inpatient/outpatient nutritional rehabilitation for children with baseline severe malnutrition
Number of subjects: 1207
Study: 19398166

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine replacement therapy
Number of subjects: 0
Study: 16926171

Group type: EXPERIMENTAL
Intervention: Alcohol intervention program
Number of subjects: 82

Group type: COMPARATOR
Intervention: Coping intervention program
Number of subjects: 82

Group type: COMPARATOR
Intervention: Combination program
Number of subjects: 82
Study: 14960294

Group type: EXPERIMENTAL
Intervention: Estradiol (.1 mg/day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Combined estradiol-medroxyprogesterone
Number of subjects: 57
Study: 11502805

Group type: EXPERIMENTAL
Intervention: Dexamethasone and prednisone treatment
Number of subjects: 26
Study: 9258849

Group type: EXPERIMENTAL
Intervention: Weights group performing heavy squats
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 7953934

Group type: EXPERIMENTAL
Intervention: Comprehensive oral health care programme
Number of subjects: 212

Group type: COMPARATOR
Intervention: Non-participating control group
Number of subjects: 212
Study: 2885080

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (cisplatin and bleomycin) followed by standard therapy (surgery and postoperative radiotherapy)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy and standard therapy followed by maintenance chemotherapy (six cycles of monthly cisplatin)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 462
Study: 29884456

Group type: EXPERIMENTAL
Intervention: THC (15 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23